Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Chemoimmunotherapy.

Summary: Diffuse Large B-Cell Lymphoma (DLBCL) is a common blood cancer, but standard chemotherapy (R-CHOP) doesn't work for everyone. Doctors often struggle to predict which patients will respond to treatment and which will resist it. In this study, researchers analyzed "long noncoding RNAs" (lncRNAs)—genetic molecules that act like switches in our cells—from 75 patients. They discovered a specific pattern: patients with high levels of the lncRNAs "HOTAIR" and "MALAT1," combined with low levels of "PANDA," were significantly more likely to resist chemotherapy. Among these, the PANDA molecule was the most accurate predictor. This discovery could help doctors identify high-risk patients earlier and explore new, targeted therapies for those resistant to standard care.